Chemical formula: C₁₂H₁₇N₃O₄S Molecular mass: 299.346 g/mol PubChem compound: 104838
Imipemide interacts in the following cases:
Decreases in valproic acid levels that may fall below the therapeutic range have been reported when valproic acid was co-administered with carbapenem agents. The lowered valproic acid levels can lead to inadequate seizure control; therefore, concomitant use of imipenem and valproic acid/sodium valproate is not recommended and alternative antibacterial or anti-convulsant therapies should be considered.
There are no adequate and well-controlled studies for the use of imipenem in pregnant women. The potential risk for humans is unknown. Imipenem should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Imipenem is excreted into the mother’s milk in small quantities. Little absorption of the compound occurs following oral administration. Therefore it is unlikely that the suckling infant will be exposed to significant quantities. If the use of imipenem is deemed necessary, the benefit of breast feeding for the child should be weighed against the possible risk for the child.
There are no data available regarding potential effects of imipenem treatment on male or female fertility.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
